Cargando…

Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study

AIM: To determine the impact of allopurinol non-adherence as a proxy for uncontrolled disease on primary prevention of end-stage renal disease (ESRD). METHODS: A cohort of 2752 patients with gout diagnosis was reconstructed using the Québec Régie de l’assurance maladie du Québec and MedEcho administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Perreault, Sylvie, Nuevo, Javier, Baumgartner, Scott, Morlock, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424435/
https://www.ncbi.nlm.nih.gov/pubmed/28540203
http://dx.doi.org/10.5527/wjn.v6.i3.132
_version_ 1783235136417955840
author Perreault, Sylvie
Nuevo, Javier
Baumgartner, Scott
Morlock, Robert
author_facet Perreault, Sylvie
Nuevo, Javier
Baumgartner, Scott
Morlock, Robert
author_sort Perreault, Sylvie
collection PubMed
description AIM: To determine the impact of allopurinol non-adherence as a proxy for uncontrolled disease on primary prevention of end-stage renal disease (ESRD). METHODS: A cohort of 2752 patients with gout diagnosis was reconstructed using the Québec Régie de l’assurance maladie du Québec and MedEcho administrative databases. Eligible patients were new users of allopurinol, aged 45-85, with a diagnosis of hypertension, and treated with an antihypertensive drug between 1997 and 2007. RESULTS: Major risk factor for ESRD onset was chronic kidney disease at stages 1 to 3 [rate ratio (RR) = 8.00; 95% confidence interval (CI): 3.16-22.3 and the severity of hypertension (≥ 3 vs < 3 antihypertensives)] was a trending risk factor as a crude estimate (RR = 1.94; 95%CI: 0.68-5.51). Of 341 patients, cases (n = 22) and controls (n = 319), high adherence level (≥ 80%) to allopurinol therapy, compared with lower adherence level (< 80%), was associated with a lower rate of ESRD onset (RR = 0.35; 95%CI: 0.13-0.91). CONCLUSION: Gout control seem to be associated with a significant decreased risk of ESRD onset in hypertensive populations, further research should be conducted confirming this potential associated risk.
format Online
Article
Text
id pubmed-5424435
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-54244352017-05-24 Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study Perreault, Sylvie Nuevo, Javier Baumgartner, Scott Morlock, Robert World J Nephrol Case Control Study AIM: To determine the impact of allopurinol non-adherence as a proxy for uncontrolled disease on primary prevention of end-stage renal disease (ESRD). METHODS: A cohort of 2752 patients with gout diagnosis was reconstructed using the Québec Régie de l’assurance maladie du Québec and MedEcho administrative databases. Eligible patients were new users of allopurinol, aged 45-85, with a diagnosis of hypertension, and treated with an antihypertensive drug between 1997 and 2007. RESULTS: Major risk factor for ESRD onset was chronic kidney disease at stages 1 to 3 [rate ratio (RR) = 8.00; 95% confidence interval (CI): 3.16-22.3 and the severity of hypertension (≥ 3 vs < 3 antihypertensives)] was a trending risk factor as a crude estimate (RR = 1.94; 95%CI: 0.68-5.51). Of 341 patients, cases (n = 22) and controls (n = 319), high adherence level (≥ 80%) to allopurinol therapy, compared with lower adherence level (< 80%), was associated with a lower rate of ESRD onset (RR = 0.35; 95%CI: 0.13-0.91). CONCLUSION: Gout control seem to be associated with a significant decreased risk of ESRD onset in hypertensive populations, further research should be conducted confirming this potential associated risk. Baishideng Publishing Group Inc 2017-05-06 2017-05-06 /pmc/articles/PMC5424435/ /pubmed/28540203 http://dx.doi.org/10.5527/wjn.v6.i3.132 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Control Study
Perreault, Sylvie
Nuevo, Javier
Baumgartner, Scott
Morlock, Robert
Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
title Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
title_full Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
title_fullStr Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
title_full_unstemmed Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
title_short Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study
title_sort any link of gout disease control among hypertensive patients and onset of end-stage renal disease? results from a population-based study
topic Case Control Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424435/
https://www.ncbi.nlm.nih.gov/pubmed/28540203
http://dx.doi.org/10.5527/wjn.v6.i3.132
work_keys_str_mv AT perreaultsylvie anylinkofgoutdiseasecontrolamonghypertensivepatientsandonsetofendstagerenaldiseaseresultsfromapopulationbasedstudy
AT nuevojavier anylinkofgoutdiseasecontrolamonghypertensivepatientsandonsetofendstagerenaldiseaseresultsfromapopulationbasedstudy
AT baumgartnerscott anylinkofgoutdiseasecontrolamonghypertensivepatientsandonsetofendstagerenaldiseaseresultsfromapopulationbasedstudy
AT morlockrobert anylinkofgoutdiseasecontrolamonghypertensivepatientsandonsetofendstagerenaldiseaseresultsfromapopulationbasedstudy